Clinical Trials
3 trialsNCT07556549 2026-05-22
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Pfizer
Active not recruiting
NCT07567352 2026-05-12
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Pfizer
Active not recruiting
NCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed